“In rat primary OBs, PA treatment significantly decreased ALP activity and osteogenic gene and protein (β-catenin, RUNX2, and osterix) expression, and ALA dose-dependently restored the inhibition induced by PA.ConclusionsFO might be a potential therapeutic agent for HFD-induced bone loss, most likely by promoting osteogenesis.”